Because mutational hotspots cannot be determined, genetic testing for CCM typically involves analysis of all coding exons and exon-intron boundaries of CCM1, CCM2, and CCM3. NGS gene panel analysis has proven superior to a stepwise approach in this context (Spiegler et al., 2018b). This evidence concerns the gene CCM2 and cerebral cavernous malformation.